Neuroscience
Fig. 5 (Davis et al., 1992): Drawing from an original photograph by Kirschbaum of one of his subjects undergoing transmogrification after experimental exposure to amplified illumination at lunar wavelengths.
VERY ORIGINAL RESEARCH * RECHERCHES EXTRAORDINAIRESFrom the Orphan Drug Research Institute (an affiliate of Yoknapatawpha University), 666 Rowanoak Circle, Jefferson, Miss. This is the first report from the institute's Orphan Drug Development Program.
Fig. 1 (Davis et al., 1992): Structural formulas of endogenous lycanthropogens.
The full paper is available as an open access article, so don't delay in reading this RECHERCHES EXTRAORDINAIRES in its entirety. It's Halloween, and there's a Bad Moon Rising...
Reference
Davis WM, Wellwuff HG, Garew L, Kydd OU. (1992). Psychopharmacology of lycanthropy. CMAJ Apr 1;146(7):1191-7.
Teen Wolf, shown Car Surfin' USA (Kids! Don't try this at home)...
- Werewolves Of London, Ontario
An American Werewolf in London In the last post, we learned about the Psychopharmacology of Lycanthropy (and "endogenous lycanthropogens") from the April 1, 1992 issue of the Canadian Medical Association Journal (Davis et al., 1992). In a more serious...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Pharmacologic Strategies
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs British Journal of Clinical Pharmacology. 2011 Oct 28; Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F Abstract Current approved drug treatments...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Neuropsychology Abstract Of The Day: Epilepsy
Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, Motamedi GK, Evans BM, & Baum C. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology. 2007 Nov 27; 69(22): 2076-2084. Department of Neurology, University...
- Parkinson Disease
From an NIH press release on 04 July 2006: Dopamine Drug Leads to New Neurons and Recovery of Function in Rat Model of Parkinson's Disease In preliminary results, researchers have shown that a drug which mimics the effects of...
Neuroscience
Psychopharmacology of Lycanthropy
Fig. 5 (Davis et al., 1992): Drawing from an original photograph by Kirschbaum of one of his subjects undergoing transmogrification after experimental exposure to amplified illumination at lunar wavelengths.
VERY ORIGINAL RESEARCH * RECHERCHES EXTRAORDINAIRESFrom the Orphan Drug Research Institute (an affiliate of Yoknapatawpha University), 666 Rowanoak Circle, Jefferson, Miss. This is the first report from the institute's Orphan Drug Development Program.
Objective: To develop pharmacotherapies for the orphan disease lycanthropy through the pursuit of the etiologic hypothesis of a genetically determined hypersecretion of endogenous lycanthropogens.
Design: Quadruple-blind, Rubik's Cube matrix analysis.
Setting: Community practice and malpractice.
Participants: Subjects selected from inbred Ruficolla populations in Mississippi, Georgia, North Carolina and Minnesota. All who entered the study finished it.
Interventions: Chemical screening of blood samples over a hypothesized secretory cycle of lycanthropogen peaking on the day of maximum lunar illumination. Administration of synthetic lycanthropogens for behavioural testing. Experimental lycosomatization through the illumination method of Kirschbaum.
Outcome measures: None were post hoc, but some are still in hock.
Main results: Two putative lycanthropogens were isolated from the blood samples. Structural elucidation and synthesis permitted animal and clinical trials; in each of these, behavioural dysfunction was observed. Antilycanthropogen strategies included application of the principle of caged compounds and generation of a therapeutic immunoglobulin. The effects of a newly developed antihirsutic agent seemed promising. An interaction of the lycanthropogen-secretion system and ethanol was noted, which may explain behavioural aspects of alcoholism.
Conclusions: The incidence of lycomania in North America is underestimated. Soon-to-be-available pharmacotherapies should promote its early detection and treatment. Full control may depend upon advances in gene therapy.
Fig. 1 (Davis et al., 1992): Structural formulas of endogenous lycanthropogens.
The full paper is available as an open access article, so don't delay in reading this RECHERCHES EXTRAORDINAIRES in its entirety. It's Halloween, and there's a Bad Moon Rising...
Reference
Davis WM, Wellwuff HG, Garew L, Kydd OU. (1992). Psychopharmacology of lycanthropy. CMAJ Apr 1;146(7):1191-7.
Teen Wolf, shown Car Surfin' USA (Kids! Don't try this at home)...
- Werewolves Of London, Ontario
An American Werewolf in London In the last post, we learned about the Psychopharmacology of Lycanthropy (and "endogenous lycanthropogens") from the April 1, 1992 issue of the Canadian Medical Association Journal (Davis et al., 1992). In a more serious...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Pharmacologic Strategies
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs British Journal of Clinical Pharmacology. 2011 Oct 28; Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F Abstract Current approved drug treatments...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Neuropsychology Abstract Of The Day: Epilepsy
Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, Motamedi GK, Evans BM, & Baum C. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology. 2007 Nov 27; 69(22): 2076-2084. Department of Neurology, University...
- Parkinson Disease
From an NIH press release on 04 July 2006: Dopamine Drug Leads to New Neurons and Recovery of Function in Rat Model of Parkinson's Disease In preliminary results, researchers have shown that a drug which mimics the effects of...